PMID: 9646059Jul 1, 1998Paper

Beneficial hemodynamic effects of nicorandil in a canine model of acute congestive heart failure: comparison with nitroglycerin and cromakalim

Fundamental & Clinical Pharmacology
K NoguchiM Sakanashi

Abstract

Comparative hemodynamic effects of nicorandil (NCR), nitroglycerin (NTG) and cromakalim (CRM) were examined in a canine model of acute congestive heart failure (CHF). CHF was produced by injections of saponin into coronary arteries of anesthetized dogs followed by volume loading and continuous i.v. infusion of methoxamine. After the treatment, aortic blood flow (AoF), left ventricular dP/dt and myocardial segment shortening (SS) markedly decreased, while the left ventricular end-diastolic pressure (LVEDP), the right atrial pressure (RAP) and the systemic vascular resistance (SVR) increased. NCR (n = 6), NTG (n = 6) and CRM (n = 8), which were administered i.v. after production of CHF, caused a comparable reduction in LVEDP. NCR and CRM profoundly increased AoF and SS but NTG did only slightly. On the other hand, NTG and NCR but not CRM significantly reduced RAP. Intracoronary NCR (n = 8) exerted no or similar effects on SS as well as systemic hemodynamic indices to those observed with i.v. NCR despite distinct coronary vasodilation. These results indicate that NCR may exert beneficial hemodynamic effects in an experimental CHF mainly due to lessening both afterload and preload rather than the coronary vasodilating effect.

References

Oct 1, 1992·Journal of Cardiovascular Pharmacology·T D GilesA E Hearron
Apr 1, 1992·Journal of the American College of Cardiology·S D KatzT H LeJemtel
Feb 1, 1990·The American Journal of Cardiology·N GaliéB Magnani
Jun 1, 1990·The American Journal of Cardiology·F D TiceC V Leier
Jun 20, 1989·The American Journal of Cardiology·N Taira
Jun 20, 1989·The American Journal of Cardiology·A C SolalR Gourgon
Aug 1, 1986·Naunyn-Schmiedeberg's Archives of Pharmacology·M SakanashiJ Nakasone
May 1, 1984·Journal of Cardiovascular Pharmacology·K A LampingG J Gross
May 30, 1996·The American Journal of Cardiology·U Elkayam

❮ Previous
Next ❯

Citations

Nov 24, 2007·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·R Abu-Nader, R Patel
Jan 16, 2009·Journal of Veterinary Internal Medicine·M OuelletG Beauchamp
May 24, 2013·Annals of Thoracic and Cardiovascular Surgery : Official Journal of the Association of Thoracic and Cardiovascular Surgeons of Asia·Meletios KanakisFotios Mitropoulos
Oct 8, 2014·Veterinary Radiology & Ultrasound : the Official Journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association·Mitzi Sarahí Anaya GarcíaRicardo Palacios Aguiar
May 4, 2018·Journal of Applied Physiology·Paul AvanPierre Denise
Nov 13, 2019·Journal of the American Animal Hospital Association·Ron AchielRobert A Sanders

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.